IBDEI1T7 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31893,1,3,0)
 ;;=3^War op involving fragments from munitions, milt, sequela
 ;;^UTILITY(U,$J,358.3,31893,1,4,0)
 ;;=4^Y36.250S
 ;;^UTILITY(U,$J,358.3,31893,2)
 ;;=^5061639
 ;;^UTILITY(U,$J,358.3,31894,0)
 ;;=Y36.260S^^181^1975^8
 ;;^UTILITY(U,$J,358.3,31894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31894,1,3,0)
 ;;=3^War op w fragmt of improv explosv device, milt, sequela
 ;;^UTILITY(U,$J,358.3,31894,1,4,0)
 ;;=4^Y36.260S
 ;;^UTILITY(U,$J,358.3,31894,2)
 ;;=^5061645
 ;;^UTILITY(U,$J,358.3,31895,0)
 ;;=Y36.270S^^181^1975^3
 ;;^UTILITY(U,$J,358.3,31895,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31895,1,3,0)
 ;;=3^War op involving fragments from weapons, milt, sequela
 ;;^UTILITY(U,$J,358.3,31895,1,4,0)
 ;;=4^Y36.270S
 ;;^UTILITY(U,$J,358.3,31895,2)
 ;;=^5061651
 ;;^UTILITY(U,$J,358.3,31896,0)
 ;;=Y36.290S^^181^1975^4
 ;;^UTILITY(U,$J,358.3,31896,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31896,1,3,0)
 ;;=3^War op involving oth explosn and fragments, milt, sequela
 ;;^UTILITY(U,$J,358.3,31896,1,4,0)
 ;;=4^Y36.290S
 ;;^UTILITY(U,$J,358.3,31896,2)
 ;;=^5061657
 ;;^UTILITY(U,$J,358.3,31897,0)
 ;;=B18.2^^182^1976^26
 ;;^UTILITY(U,$J,358.3,31897,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31897,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,31897,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,31897,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,31898,0)
 ;;=C44.99^^182^1976^48
 ;;^UTILITY(U,$J,358.3,31898,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31898,1,3,0)
 ;;=3^Skin Cancer NOS
 ;;^UTILITY(U,$J,358.3,31898,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,31898,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,31899,0)
 ;;=E11.9^^182^1976^15
 ;;^UTILITY(U,$J,358.3,31899,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31899,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,31899,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,31899,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,31900,0)
 ;;=E11.40^^182^1976^16
 ;;^UTILITY(U,$J,358.3,31900,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31900,1,3,0)
 ;;=3^Diabetes Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,31900,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,31900,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,31901,0)
 ;;=E78.2^^182^1976^27
 ;;^UTILITY(U,$J,358.3,31901,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31901,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,31901,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,31901,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,31902,0)
 ;;=E78.5^^182^1976^28
 ;;^UTILITY(U,$J,358.3,31902,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31902,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,31902,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,31902,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,31903,0)
 ;;=E66.3^^182^1976^42
 ;;^UTILITY(U,$J,358.3,31903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31903,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,31903,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,31903,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,31904,0)
 ;;=D64.9^^182^1976^3
 ;;^UTILITY(U,$J,358.3,31904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31904,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,31904,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,31904,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,31905,0)
 ;;=F17.200^^182^1976^39
 ;;^UTILITY(U,$J,358.3,31905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31905,1,3,0)
 ;;=3^Nicotine Dependence,Unspec
 ;;^UTILITY(U,$J,358.3,31905,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,31905,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,31906,0)
 ;;=F17.229^^182^1976^38
 ;;^UTILITY(U,$J,358.3,31906,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI1T7
